Certified by Founder Lodge
Indapta Therapeutics
United States - Seattle & Houston
START UP
1 Disclosed Funding Rounds $22,500,000
0 Participating Investments
-
Founded date
2017
-
Operating Status
Active
-
Last Funding Type
Seed
-
Company Type
For Profit
- Website
- Contact
- Social Links
Indapta's allogeneic g-NK cells have highly potent ADCC activity, making them the ideal therapy to combine with IgG1 monoclonal antibodies, ADCs, or innate immune cell engager molecules.
| Date | Round | Raised | Participating Investors |
|---|---|---|---|
| December, 18 ,2024 | Unknown | $22,500,000 |
Vertex Ventures HC
RA Capital Management, L.P.
IDRx
CAMP4 Therapeutics
Delfi Diagnostics
xilis
Manifold Bio
Retellio | $1,300,000 | (Dec 18, 2024)
Fluid Biomed Inc. | $27,000,000 | (Dec 18, 2024)
CredibleX | $55,000,000 | (Dec 18, 2024)
FastWave Medical | $19,000,000 | (Dec 18, 2024)
Chargezoom | $11,500,000 | (Dec 18, 2024)
